Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study - Summary - MDSpire
Advertisement
Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study
To evaluate the real-world acute effects of finerenone on blood pressure (BP) and heart rate (HR) in hospitalized patients with type 2 diabetes (T2D).
Approach:
Study Design: Retrospective observational study of T2D patients initiated on finerenone as part of standard clinical care.
Cohorts: Patients grouped into five cohorts based on treatment initiation day (Day 1 to Day 5).
Monitoring: Daily monitoring of morning and afternoon systolic BP, diastolic BP, and HR for 7 days.
Baseline Assessment: Evaluation of baseline characteristics including urinary albumin-to-creatinine ratio (UACR), serum potassium, and RAAS markers.
Key Findings:
Finerenone was mainly prescribed to patients with notably high UACR (average grade III; p < 0.0001 compared to non-users), indicating its targeted use for high-risk kidney patients.
Significant decreases in both SBP and DBP were observed after adding finerenone, particularly within the first 24–48 hours (p < 0.05 to p < 0.0001).
HR remained stable during the initial days of therapy.
The distribution of background medications stayed consistent during finerenone treatment, suggesting that the hemodynamic improvements were not due to changes in other antihypertensive medications.
Interpretation:
Finerenone was associated with antihypertensive effects in hospitalized T2D patients with albuminuria, demonstrating its utility in managing hypertension.
Conclusion:
This real-world evidence indicates that finerenone was associated with antihypertensive effects in hospitalized T2D patients with albuminuria.
